Undervalued Australian stocks offering high dividends

Team Veye | 02-Sep-2025 Undervalued Australian stocks

A few ASX stocks with a high dividend yield are the favourite of investors who like to add these to their portfolio for the dual opportunity it offers.

Besides being a source of good passive income, such stocks also offer a growth opportunity in the event of these realising their full potential.

Beach Energy Ltd (ASX: BPT)

has delivered strong FY25 results, with material growth across all key metrics. Company Production rose 9% to 19.7 MMboe, while sales volumes increased by 16% to 24.7 MMboe and driving sales revenue was higher by 13% to $2.0 billion. The average realized petrol price of $10.7/GJ which was up 13% year over year, helped to support the 20% increase in underlying EBITDA to $1.1 billion. Operating cash flow rose 46% to $1.1 billion, while pre-growth free cash flow more than increased fourfold to $657 million, indicating better margins and capital discipline. The company's record fully franked final dividend of 6 cents per share, a 200% increase, highlighted its strong financial position and commitment to capital returns. These results demonstrate Beach Energy's better efficiency, operational expertise, and ability to capitalize on favourable market conditions which is preparing the company for long-term value creation and expansion.

Atlas Arteria (ASX: ALX)

has delivered a steady H1 FY25 performance by having strong revenue and cash flow growth despite one-off tax impacts. Strong traffic trends assisted the company report proportional toll revenue of $954.5 million, an 8.1% increase over H1 FY24. While free cash flow increased 9.0% to $281.0 million, or 19.4 cents per security, proportional EBITDA increased 7.8% to $729.2 million. The French Temporary Supplemental Tax was the main cause of the net profit after tax, which was $73.3 million, a 32.9% decrease from the previous year. As anticipated, centralised costs came to $19.7 million. In keeping with H1 FY24, the Board declared a distribution of 20.0 cps, which reflects ALX's continuing focus on steady shareholder returns.

Healius Limited (ASX: HLS)

has reported its FY25 results which has reflected solid top-line growth despite ongoing challenges. While Agilex revenue decreased 3.3%, pathology revenue (ex-Agilex) increased 6.0%, adding significantly to the group's 5.7% year-on-year increase in revenue to $1.34 billion. Despite a 27.2% decline, underlying EBIT of $17.1 million was in line with consensus expectations, while underlying EBITDA came in at $239.3 million, down 4.0% from the previous corresponding period. The reported EBIT loss of $527.0 million was driven by non-underlying and discontinued operations, such as the sale of Lumus Imaging, digital investments, restructure, and impairment charges. The group's reported EBITDA loss was $302.7 million, a decrease from $410.4 million the year before. Crucially, Healius finished the period with $57.2 million in net cash as of June 30, 2025, ensuring its continued execution of its strategy in pathology and debt reduction efforts.

(Source: Company Announcements)

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

veye logo

Grab Your Free Report On 5 ASX Dividend Stocks To Buy In 2025

(+61)

SALE IS LIVE

Limited Time Deal:   Over 72% OFF

DIVIDEND
STOCKS REPORT

Dividend-Investor-Report

Each week we cover companies offering a good combination of growth & dividends, maintaining a balance between stable 'cash flow' and riskier 'raising stars'. Our guidance helps you choose companies with regular dividends and opportunities for lower-risk capital growth.

  • The best High Yield Dividend Stocks picked by our team of analysts every Week.
  • Detailed in-depth Analysis with our expert Recommendations Buy, Hold or Sell.
  • Free Daily Analysis Report to keep up with the latest on what's hot and what's not.
  • Gain instant access to a wide range of Dividend Share Reports, exclusive to members only.
Frequency: Every Tuesday